Literature DB >> 21604085

Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.

K R Hjøllund, C F Deacon, J J Holst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21604085     DOI： 10.1007/s00125-011-2168-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats.

Authors:  L Simonsen; S Pilgaard; R D Carr; A B Kanstrup; J J Holst; C F Deacon
Journal:  Horm Metab Res       Date:  2009-07-03       Impact factor: 2.936

2.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.

Authors:  A Vella; P Shah; R Basu; A Basu; J J Holst; R A Rizza
Journal:  Diabetes       Date:  2000-04       Impact factor: 9.461

3.  Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

Authors:  L Hansen; C F Deacon; C Orskov; J J Holst
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

4.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

Authors:  C F Deacon; S Wamberg; P Bie; T E Hughes; J J Holst
Journal:  J Endocrinol       Date:  2002-02       Impact factor: 4.286

5.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig.

Authors:  C F Deacon; L Pridal; L Klarskov; M Olesen; J J Holst
Journal:  Am J Physiol       Date:  1996-09

Review 6.  The incretin system and its role in type 2 diabetes mellitus.

Authors:  Jens Juul Holst; Tina Vilsbøll; Carolyn F Deacon
Journal:  Mol Cell Endocrinol       Date:  2008-08-20       Impact factor: 4.102

7.  Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Authors:  Mette Zander; Allan Christiansen; Sten Madsbad; Jens Juul Holst
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

8.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Authors:  C F Deacon; A H Johnsen; J J Holst
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958
  8 in total
  19 in total

Review 1.  Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Authors:  C Dirksen; N B Jørgensen; K N Bojsen-Møller; S H Jacobsen; D L Hansen; D Worm; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2012-04-27       Impact factor: 10.122

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle.

Authors:  Alexander T May; Molly S Crowe; Bryan A Blakeney; Sunila Mahavadi; Hongxia Wang; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2018-11-30       Impact factor: 3.750

Review 4.  The Pancreatic β-Cell: The Perfect Redox System.

Authors:  Petr Ježek; Blanka Holendová; Martin Jabůrek; Jan Tauber; Andrea Dlasková; Lydie Plecitá-Hlavatá
Journal:  Antioxidants (Basel)       Date:  2021-01-29

5.  Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Authors:  Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst
Journal:  Diabetologia       Date:  2017-07-01       Impact factor: 10.122

Review 6.  GLP-1: Molecular mechanisms and outcomes of a complex signaling system.

Authors:  Nicholas K Smith; Troy A Hackett; Aurelio Galli; Charles R Flynn
Journal:  Neurochem Int       Date:  2019-04-17       Impact factor: 3.921

Review 7.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

8.  Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.

Authors:  Caroline C Øhrstrøm; Dorte Worm; Urd Lynge Kielgast; Jens Juul Holst; Dorte L Hansen
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

Review 9.  Actions of glucagon-like peptide-1 receptor ligands in the gut.

Authors:  Jens Juul Holst; Daniel Bjørklund Andersen; Kaare Villum Grunddal
Journal:  Br J Pharmacol       Date:  2021-08-04       Impact factor: 8.739

10.  Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

Authors:  Carolyn F Deacon
Journal:  Diabetes       Date:  2012-09       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.